Access to Medicines

Civil Society on transparency, public health in TPPA; 28 Senators call for highest standards of protection IP in agreement

Submitted by Krista Cox on 18. May 2011 - 15:32

On Wednesday, May 18, 2011, eight civil society organizations submitted joint comments and recommendations on the Trans-Pacific Partnership Agreement (TPPA).

KEI comments on Tibotec voluntary licenses of a new HIV-AIDS product

Submitted by Judit Rius on 27. January 2011 - 13:07

Today, Tibotec, a subsidiary of Johnson & Johnson, announced it has signed voluntary licensing agreements with several Indian and South African generic companies to allow generic competition on a new HIV-AIDS treatment, the investigational non-nucleoside reverse transcriptase inhibitor rilpivirine hydrochloride (TMC278) (rilpivirine hydrochloride), to certain developing countries.

Why is there resistance to prize funds?

Submitted by James Love on 23. May 2010 - 1:49

I was recently asked the following question:

Jamie
What is your view on the treatment of prize funds? By all standards it is treated as a radical off the wall proposal when in fact it is market based. Why is there so much resistance?

My response was as follows:

Dec 9, 2009 Wikileaks documents related to the WHO EWG

Submitted by Malini Aisola on 21. January 2010 - 9:30

On December 9, 2009, Wikileaks posted five sensitive documents related to the WHO Expert Working Group (EWG) on R&D Financing:

  • a non-public draft report of the WHO EWG
  • a non-public Comparative Analysis done by the EWG
  • the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) Overview of the EWG Comparative Analysis
  • an IFPMA summary slide on the EWG Draft Report

    • Open Letter to the WHO EB from Cecilia López Montaño, EWG member

    Submitted by Malini Aisola on 17. January 2010 - 20:54

    The following is a letter sent by Cecilia López Montaño, a member of the WHO Expert Working Group on R&D Financing to the WHO Executive Board:

    Bogotá. Colombia. January 15th 2010

    Dear members of the Executive Board:

    I am Cecilia López Montaño, senator of the Colombian Congress and member of the Expert Working Group on Research and Development Financing of the World Health Organization, in representation of the point of view of developing countries, I assume.

    Can the U.S. realistically honor commitments to fund treatment for AIDS in developing countries without generic products?

    Submitted by James Love on 12. January 2010 - 22:34
    Yes
    14% (54 votes)
    No
    86% (334 votes)
    Total votes: 388

    KEI Statement on UNITAID Decision to Approve Creation of a Patent Pool for AIDS medicines

    Submitted by James Love on 15. December 2009 - 1:22

    On Monday, December 14, the UNITAID board passed a resolution to establish a Patent Pool for AIDS medicines. The decision caped a dramatic debate on the proposal, which had been before UNITAID since 2006, and had been discussed in other fora since 2002. The following is a statement by KEI on the UNITAID decision, followed by background on the UNITAID patent pool proposal, including a copy of the UNITAID press release.

    Statement of James Love, Director of KEI, on the UNITAID Patent Pool:

    Speech of Mike Foster, UK Minister for International Development at launch of Industry Government Forum on Access to Medicines

    Submitted by thiru on 21. October 2009 - 4:32

    On October 12, 2009, the "Industry Government Forum on Access to Medicines" (IGFAM) was launched. The UK Minister for International Development, MP Mike Foster made a a speech to launch this initiative which is reproduced below.

    Presentations were also made by Pfizer (Ponni Subbiah), GSK (Abbas Hussain), Rajiv Venkayya (Gates Foundation), Prashant Yadav (Massachusetts Institute of Technology) and Suerie Moon (Research Fellow and Doctoral Candidate, Kennedy School of Government, Harvard University).

    The Right to Development Criteria, applied to TDR and the Global Fund

    Submitted by James Love on 18. September 2009 - 5:50

    For several years, the UN Human Rights Council (HRC) has been working on mechanisms to implement a 1986 UN Resolution on the "Right to Development." To this end, the HRC has created a Working Group on the Right to Development, and a High Level Task Force On The Implementation Of The Right To Development.

    Letter to WHO on the Essential Medicines List

    March 2, 2007
     
    Secretary of the Expert Committee on the
    Selection and Use of Essential Medicines (2007)
    Department of Medicines Policy and Standards (PSM)
    Health Technology & Pharmaceuticals
    World Health Organization
    CH-1211 Geneva 27
    Switzerland

    Via e-mail:  emisecretariat@who.int

    RE: Request for changes in the WHO Model EML

     

    Syndicate content